Literature DB >> 12589574

Sleep disturbances in Parkinsonism.

J J M Askenasy1.   

Abstract

The present article is meant to suggest an approach to the guidelines for the therapy of sleep disturbances in Parkinson's Disease (PD) patients.The factors affecting the quality of life in PD patients are depression, sleep disturbances and dependence. A large review of the literature on sleep disturbances in PD patients, provided the basis for the following classification of the sleep-arousal disturbances in PD patients. We suggest a model based on 3 steps in the treatment of sleep disturbances in PD patients. This model allowing the patient, the spouse or the caregiver a quiet sleep at night, may postpone the retirement and the institutionalization of the PD patient. I. Correct diagnosis of sleep disorders based on detailed anamnesis of the patient and of the spouse or of the caregiver. One week recording on a symptom diary (log) by the patient or the caregiver. Correct diagnosis of sleep disorders co morbidities. Selection of the most appropriate sleep test among: polysomnography (PSG), multiple sleep latency test (MSLT), multiple wake latency test (MWLT), Epworth Sleepiness Scale, actigraphy or video-PSG. II. The nonspecific therapeutic approach consists in: a) Checking the sleep effect on motor performance, is it beneficial, worse or neutral. b) Psycho-physical assistance. c) Dopaminergic adjustment is necessary owing to the progression of the nigrostriatal degeneration and the increased sensitivity of the terminals, which alter the normal modulator mechanisms of the motor centers in PD patients. Among the many neurotransmitters of the nigro-striatal pathway one can distinguish two with a major influence on REM and NonREM sleep. REM sleep corresponds to an increased cholinergic receptor activity and a decreased dopaminergic activity. This is the reason why REM sleep deprivation by suppressing cholinergic receptor activity ameliorates PD motor symptoms. L-Dopa and its agonists by suppressing cholinergic receptors suppress REM sleep. The permanent adjustment according to the progression of the degenerative process of the disease will diminishe aggravation. The following types of sleep-arousal disturbances have to be considered in PD patients: - Sleep Disturbances, Light Fragmented Sleep (LFS), Abnormal Motor Activity During Sleep (AMADS), REM Behavior Disorders (RBD), Sleep Related Breathing Disorders (SRBD), Sleep Related Hallucinations (SRH), Sleep Related Psychotic Behavior (SRPB). - Arousal Disturbances, Sleep Attacks (SA), Excessive Daytime Sleepiness (EDS), Each syndrome has to receive a score according to its severity. III. The specific therapy consists in: LFS: Benzodiazepines & Nondiazepines. AMADS: Clonazepam, Opioid, Apomorphine infusion; RBD: Clonazepam and dopaminergic agonists; SRBD: CPAP, UPPP, nasal interventions, losing weight; SRH: Clozapine, Risperidone; SRPD: Nortriptyline, Clozapine, Olanzepine; SA-adjustment; EDS-arousing drugs. Each therapeutic approach must be tailored to the individual PD patient.

Entities:  

Mesh:

Year:  2003        PMID: 12589574     DOI: 10.1007/s007020300001

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  9 in total

1.  Sleep in Parkinson's disease: a comparison of actigraphy and subjective measures.

Authors:  K Stavitsky; J L Saurman; P McNamara; A Cronin-Golomb
Journal:  Parkinsonism Relat Disord       Date:  2010-03-03       Impact factor: 4.891

2.  Sleep quality in Parkinson disease: an examination of clinical variables.

Authors:  Karina Stavitsky; Alice Cronin-Golomb
Journal:  Cogn Behav Neurol       Date:  2011-06       Impact factor: 1.600

Review 3.  Sleep as a Therapeutic Target in the Aging Brain.

Authors:  Thierno M Bah; James Goodman; Jeffrey J Iliff
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

4.  Neurotoxic lesions at the ventral mesopontine junction change sleep time and muscle activity during sleep: an animal model of motor disorders in sleep.

Authors:  Y-Y Lai; K-C Hsieh; D Nguyen; J Peever; J M Siegel
Journal:  Neuroscience       Date:  2008-04-16       Impact factor: 3.590

5.  Prospective assessment of subjective sleep benefit in Parkinson's disease.

Authors:  Merel M van Gilst; Bastiaan R Bloem; Sebastiaan Overeem
Journal:  BMC Neurol       Date:  2015-01-16       Impact factor: 2.474

Review 6.  Sleep Disturbance as Potential Risk and Progression Factor for Parkinson's Disease.

Authors:  Nicolaas I Bohnen; Michele T M Hu
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

7.  Neurophysiology of sleep and wakefulness: basic science and clinical implications.

Authors:  Jonathan R L Schwartz; Thomas Roth
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

8.  Alterations in Polysomnographic (PSG) profile in drug-naïve Parkinson's disease.

Authors:  Sanju P Joy; Sanjib Sinha; Pramod Kumar Pal; Samhita Panda; Mariamma Philip; Arun B Taly
Journal:  Ann Indian Acad Neurol       Date:  2014-07       Impact factor: 1.383

9.  Validation of the Korean Version of the Scales for Outcomes in Parkinson's Disease-Sleep.

Authors:  Young Hee Sung; Hee Jin Kim; Seong Beom Koh; Joong Seok Kim; Sang Jin Kim; Sang Myung Cheon; Jin Whan Cho; Yoon Joong Kim; Hyeo Il Ma; Mee Young Park; Jong Sam Baik; Phil Hyu Lee; Sun Ju Chung; Jong Min Kim; In Uk Song; Han Joon Kim; Ji Young Kim; Do Young Kwon; Jae Hyeok Lee; Jee Young Lee; Ji Seon Kim; Ji Young Yun; Jin Yong Hong; Mi Jung Kim; Jinyoung Youn; Ji Sun Kim; Eung Seok Oh; Hui Jun Yang; Won Tae Yoon; Sooyeoun You; Kyum Yil Kwon; Hyung Eun Park; Su Yun Lee; Younsoo Kim; Hee Tae Kim; Tae Beom Ahn
Journal:  J Korean Med Sci       Date:  2018-01-08       Impact factor: 2.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.